Zonagen Announces Positive Top-Line Results Of Androxal(TM) Study

Published: Feb 03, 2006

THE WOODLANDS, Texas--(BUSINESS WIRE)--Feb. 3, 2006--Zonagen, Inc. (Nasdaq:ZONA) and (PCX:ZONA), a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders, today announced positive top-line results of an open-label study of Androxal(TM), the company's candidate for the treatment of testosterone deficiency. This study was designed to evaluate the effect of Androxal(TM) on the testosterone levels of 13 men with normal, borderline or low testosterone.

Back to news